Cargando…
Letter to the editor in re: Mohan et al., 2020 ‘dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels’
Autores principales: | Romach, EH, Posobiec, LM, Bloomer, JC, Zamek-Gliszczynski, MJ, Stanislaus, DJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050848/ https://www.ncbi.nlm.nih.gov/pubmed/33857900 http://dx.doi.org/10.1016/j.ebiom.2021.103335 |
Ejemplares similares
-
In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”
por: Mohan, H., et al.
Publicado: (2021) -
Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels
por: Mohan, Haneesha, et al.
Publicado: (2020) -
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016) -
Obituary: Dr. Mohan B. Gharpuray
por: Sardesai, Vidyadhar
Publicado: (2013) -
“Manual of ICU Procedures” edited by Mohan Gurjar
por: Bhatia, Nidhi
Publicado: (2018)